What are the Future Directions for Ivacaftor in Pediatrics?
Ongoing research aims to expand the use of ivacaftor to younger age groups and additional CFTR mutations. Combination therapies involving ivacaftor and other CFTR modulators are being explored to provide even greater benefits for children with cystic fibrosis. These advancements hold promise for further improving the health and quality of life of pediatric patients.
